Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc. (T:BHC)

Business Focus: Pharmaceuticals

This company is also listed in the United States as BHC on the NYSE. Click here to get the live US quote and see if there are any SEC insider filings..
Oct 28, 2019 04:01 pm ET
Ahead of World Psoriasis Day, Bausch Health, Canada announces that SILIQ® (brodalumab) is now covered on most drug benefit formularies in Canada
Decision by majority of provincial governments to publicly list the drug ensures improved treatment access for nearly 800,000 Canadians currently living with plaque psoriasis1,2
Oct 17, 2019 10:15 am ET
Bausch Health Announces Updated Health Canada Safety Information for ELIDEL®
TOPICAL ATOPIC DERMATITIS TREATMENT, ELIDEL® NOW AVAILABLE FOR CHILDREN THREE MONTHS AND OVER
Apr 25, 2019 01:29 pm ET
IIROC Trade Resumption - BHC
TORONTO, April 25, 2019 /CNW/ - Trading resumes in:
Apr 25, 2019 01:16 pm ET
IIROC Trading Halt - BHC
TORONTO, April 25, 2019 /CNW/ - The following issues have been halted by IIROC:
Jan 08, 2019 06:30 am ET
Bausch Health's Canadian business positioned for growth in 2019
LAVAL, QC, Jan. 8, 2019 /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is positioned for growth in Canada in 2019 under a new name, Bausch Health, Canada inc. with a strong pipeline of products and a well-established manufacturing presence in the country.
Jan 03, 2019 06:30 am ET
Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma
LAVAL, QC, Jan. 3, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health (NYSE : BHC) (TSX : BHC) today announced that on December 27, 2018, Health Canada issued the Notice of Compliance (NOC) for VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%). VYZULTA™, the first prostaglandin analog with one of its metabolites being Nitric Oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.i VYZULTA™ is the first new innovative treatment for open-angle
Sep 27, 2018 07:45 am ET
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (“Salix”), one of...
Aug 20, 2018 07:00 am ET
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a...